Viridian Therapeutics Inc. has announced the successful submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for veligrotug, its investigational therapy for thyroid eye disease (TED). The submission is supported by positive results from two pivotal phase 3 trials, THRIVE and THRIVE-2, which met all primary and secondary endpoints. Viridian has also requested Priority Review, which, if granted, could lead to a potential commercial launch of veligrotug in mid-2026, pending FDA approval. No grant or funding from multiple organizations was mentioned in the announcement.